Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 96.43% is in line with its 5-year average of 96.54%, around the middle of its 5-year range (87.37%–103.94%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.14% above its 12-month average of 95.34%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 96.40%.
GROSS MARGIN
96.43%
GROSS MARGIN AVG TTM
95.34%
GROSS MARGIN AVG 3Y
98.04%
GROSS MARGIN AVG 5Y
96.54%
GROSS MARGIN AVG 10Y
98.38%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.14%
CURRENT VS 3Y AVG
-1.64%
CURRENT VS 5Y AVG
-0.11%
CURRENT VS 10Y AVG
-1.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+134.02%
vs the sector median at left
Market Cap
$471.57M
Gross Margin
52.05%
TTM Avg
54.84%
3Y Avg
54.67%
5Y Avg
54.23%
Market Cap
$472.23M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$469.12M
Gross Margin
33.94%
TTM Avg
26.16%
3Y Avg
30.65%
5Y Avg
37.85%
Market Cap
$475.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
20.00%
Market Cap
$465.75M
Gross Margin
87.96%
TTM Avg
85.84%
3Y Avg
84.92%
5Y Avg
81.46%
Market Cap
$483.54M
Gross Margin
74.83%
TTM Avg
73.30%
3Y Avg
73.96%
5Y Avg
75.53%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arvinas, Inc. (ARVN) | $471.65M | 96.43% | 95.34% | 98.04% | 96.54% |
| Cerus Corporation (CERS)vs › | $471.57M | 52.05% | 54.84% | 54.67% | 54.23% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | 0.00% | 0.00% | 0.00% | 0.00% |
| Alpha Teknova, Inc. (TKNO)vs › | $469.12M | 33.94% | 26.16% | 30.65% | 37.85% |
| Kamada Ltd. (KMDA)vs › | $467.90M | 40.82% | 42.91% | 40.22% | 37.63% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | 0.00% | 0.00% | 25.00% | 20.00% |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | 87.96% | 85.84% | 84.92% | 81.46% |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 74.83% | 73.30% | 73.96% | 75.53% |
| Evolus, Inc. (EOLS)vs › | $486.01M | 66.25% | 66.66% | 65.82% | 64.54% |
| NRC Health (NRC)vs › | $452.54M | 56.33% | 58.27% | 60.30% | 61.48% |
Gross Margin
96.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 96.40% |
| 2026-03-31 | 92.95% |
| 2025-12-31 | 87.37% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 97.78% |
| 2024-03-31 | 93.28% |
| 2023-12-31 | 103.94% |
| 2023-09-30 | 95.09% |
| 2023-06-30 | 97.06% |
| 2023-03-31 | 94.77% |
| 2022-12-31 | 94.47% |
| 2022-09-30 | 93.67% |
| 2022-06-30 | 94.38% |
| 2022-03-31 | 92.08% |
| 2021-12-31 | 94.08% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
